EcoDrugPlus

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSGMOG00000003491
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSGMOG00000007425
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase I, Like

Ensembl ID : ENSGMOG00000017862
Gene Symbol: TOP1L
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSGMOG00000008880
Gene Symbol: TOP2A
2 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSGMOG00000009851
Gene Symbol: TOP2B
3 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSGMOG00000009981
Gene Symbol: EML4
1 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSGMOG00000006970
Gene Symbol: EPHA3
3 Cross references
212 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSGMOG00000011897
Gene Symbol: FAUA
2 Cross references
301 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSGMOG00000011103
Gene Symbol: FYNA
3 Cross references
191 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSGMOG00000001417
Gene Symbol: FYNB
3 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSGMOG00000023683
Gene Symbol: GPR84
1 Cross references
123 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSGMOG00000028999
Gene Symbol: GPR84
1 Cross references
123 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).